Table 2. Response in 74 patients at the end of treatment (surgery and chemotherapy) by FANCF status (excludes 21 uninformative patients).
|
Cisplatin+cyclophosphamidea
|
Cisplatin+paclitaxel
|
|||
|---|---|---|---|---|
| Response (WHO) | FANCF− | FANCF+ | FANCF− | FANCF+ |
| CR | 8 (26.7) | 0 | 7 (18.9) | 1 (33.3) |
| PR | 5 (26.7) | 1 (25) | 4 (10.8) | 0 |
| SD | 1 (3.3) | 0 | 2 (5.4) | 1 (33.3) |
| NED | 3 (10) | 0 | 10 (27.0) | 0 |
| PD | 2 (6.7) | 3 (75) | 3 (8.1) | 0 |
| Missing | 1 (3.3) | 0 | 0 | 0 |
| NE | 10 (33.3) | 0 | 11 (29.7) | 1 (33.3) |
CR=complete response; NE=not evaluable; NED=no evaluable disease; PD=progressive disease; PR=partial response; SD=static disease.
a
Association between negative FANCF status and response (CR+PR+SD vs PD, excluding NE and NED) P=0.0098. There was no correlation between response and methylation status in the cisplatin and paclitaxel group (P=0.5023).